Header Logo

Connection

JOHN VIERLING to Male

Back to Details
This is a "connection" page, showing publications JOHN VIERLING has written about Male.
JOHN VIERLING
Connection Strength
0.514
Male
  1. Primary biliary cholangitis. Lancet. 2024 09 14; 404(10457):1053-1066.
    View in: PubMed
    Score: 0.035
  2. Prevalence and clinical significance of portal inflammation, portal plasma cells, interface hepatitis and biliary injury in liver biopsies from patients with non-alcoholic steatohepatitis. Pathology. 2022 Oct; 54(6):686-693.
    View in: PubMed
    Score: 0.030
  3. Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis. Dig Dis Sci. 2018 03; 63(3):665-675.
    View in: PubMed
    Score: 0.022
  4. Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials. J Hepatol. 2014 Aug; 61(2):200-9.
    View in: PubMed
    Score: 0.017
  5. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. J Hepatol. 2014 Apr; 60(4):748-56.
    View in: PubMed
    Score: 0.017
  6. Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. Liver Int. 2014 May; 34(5):707-19.
    View in: PubMed
    Score: 0.016
  7. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology. 2012 Aug; 56(2):464-73.
    View in: PubMed
    Score: 0.015
  8. Hepatitis B and hepatitis C prevalence and treatment referral among Asian Americans undergoing community-based hepatitis screening. Am J Public Health. 2010 Apr 01; 100 Suppl 1:S118-24.
    View in: PubMed
    Score: 0.013
  9. Comparison of the applicability of two prognostic scoring systems in patients with fulminant hepatic failure. Korean J Intern Med. 2007 Jun; 22(2):93-100.
    View in: PubMed
    Score: 0.011
  10. Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies. Hepatol Commun. 2026 May 01; 10(5).
    View in: PubMed
    Score: 0.010
  11. Liver Biopsy Features May Help Distinguish Drug-Induced Autoimmune-Like Hepatitis From Idiopathic Autoimmune Hepatitis. Arch Pathol Lab Med. 2026 Jan 14; 150(6):448-456.
    View in: PubMed
    Score: 0.010
  12. Statin Use Is Associated With Protection Against Acute Cholangitis in Patients With Primary Sclerosing Cholangitis: A Multicenter Retrospective Cohort Study. Clin Transl Gastroenterol. 2025 Apr 01; 16(4):e00816.
    View in: PubMed
    Score: 0.009
  13. Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA). Gastroenterology. 2024 10; 167(5):1008-1018.e5.
    View in: PubMed
    Score: 0.009
  14. Primary biliary cirrhosis and autoimmune cholangiopathy. Clin Liver Dis. 2004 Feb; 8(1):177-94.
    View in: PubMed
    Score: 0.008
  15. Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial. Lancet Gastroenterol Hepatol. 2023 12; 8(12):1118-1128.
    View in: PubMed
    Score: 0.008
  16. Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE). PLoS One. 2021; 16(11):e0260320.
    View in: PubMed
    Score: 0.007
  17. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol. 2021 06; 74(6):1344-1354.
    View in: PubMed
    Score: 0.007
  18. Combined Lung-Liver and Delayed Kidney Transplantation for Cystic Fibrosis Clinical Approach and Outcome: A Case Report. Transplant Proc. 2020 Nov; 52(9):2824-2826.
    View in: PubMed
    Score: 0.006
  19. Case studies of the hepatitis B patient: a panel discussion. Semin Liver Dis. 2000; 20 Suppl 1:29-35.
    View in: PubMed
    Score: 0.006
  20. Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature. J Autoimmun. 2019 07; 101:26-34.
    View in: PubMed
    Score: 0.006
  21. No Gains in Long-term Survival After Liver Transplantation Over the Past Three Decades. Ann Surg. 2019 01; 269(1):20-27.
    View in: PubMed
    Score: 0.006
  22. Predicting Liver Allograft Discard: The Discard Risk Index. Transplantation. 2018 09; 102(9):1520-1529.
    View in: PubMed
    Score: 0.006
  23. Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials. Am J Gastroenterol. 2018 06; 113(6):863-871.
    View in: PubMed
    Score: 0.006
  24. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018 01 25; 378(4):354-369.
    View in: PubMed
    Score: 0.006
  25. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J Gastroenterol. 2018 May; 53(5):679-688.
    View in: PubMed
    Score: 0.006
  26. Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis. Transl Res. 2018 05; 195:25-47.
    View in: PubMed
    Score: 0.005
  27. Liver transplant length of stay (LOS) index: A novel predictive score for hospital length of stay following liver transplantation. Clin Transplant. 2017 Dec; 31(12).
    View in: PubMed
    Score: 0.005
  28. Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists. Clin Gastroenterol Hepatol. 2018 02; 16(2):278-287.e7.
    View in: PubMed
    Score: 0.005
  29. Seladelpar (MBX-8025), a selective PPAR-d agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol. 2017 10; 2(10):716-726.
    View in: PubMed
    Score: 0.005
  30. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol. 2017 11; 2(11):814-823.
    View in: PubMed
    Score: 0.005
  31. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017 06 01; 376(22):2134-2146.
    View in: PubMed
    Score: 0.005
  32. Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection. Ann Hepatol. 2016 Nov-Dec 2016; 15(6):834-845.
    View in: PubMed
    Score: 0.005
  33. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection. Gastroenterology. 2017 01; 152(1):164-175.e4.
    View in: PubMed
    Score: 0.005
  34. Autoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016. Hepatol Int. 2016 Nov; 10(6):909-915.
    View in: PubMed
    Score: 0.005
  35. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016 May; 63(5):1493-505.
    View in: PubMed
    Score: 0.005
  36. Detection of hepatitis C virus with RNA polymerase chain reaction in fulminant hepatic failure. Hepatology. 1995 Nov; 22(5):1379-86.
    View in: PubMed
    Score: 0.005
  37. Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial. J Viral Hepat. 2016 Feb; 23(2):80-8.
    View in: PubMed
    Score: 0.005
  38. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-na?ve patients with chronic HCV genotype 1 infection (ESSENTIAL II). Aliment Pharmacol Ther. 2015 Oct; 42(7):829-44.
    View in: PubMed
    Score: 0.005
  39. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015 May 05; 313(17):1736-44.
    View in: PubMed
    Score: 0.005
  40. Malignant vascular tumors of the liver presenting as liver failure and portal hypertension. Liver Transpl Surg. 1995 May; 1(3):156-61.
    View in: PubMed
    Score: 0.005
  41. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. J Hepatol. 2015 Jul; 63(1):30-7.
    View in: PubMed
    Score: 0.004
  42. Acute hepatitis associated with the Chinese herbal product jin bu huan. Ann Intern Med. 1994 Nov 15; 121(10):729-35.
    View in: PubMed
    Score: 0.004
  43. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015 Mar 21; 385(9973):1087-97.
    View in: PubMed
    Score: 0.004
  44. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol. 2015 Feb; 62(2):294-302.
    View in: PubMed
    Score: 0.004
  45. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2015 Jun; 64(6):948-56.
    View in: PubMed
    Score: 0.004
  46. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol. 2014 Dec; 61(6):1238-46.
    View in: PubMed
    Score: 0.004
  47. Acute liver failure due to lymphoma. A diagnostic concern when considering liver transplantation. Dig Dis Sci. 1994 Jun; 39(6):1351-8.
    View in: PubMed
    Score: 0.004
  48. Long-term follow-up of portopulmonary hypertension patients after liver transplantation. Liver Transpl. 2014 Jun; 20(6):724-7.
    View in: PubMed
    Score: 0.004
  49. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology. 2014 Aug; 147(2):366-76.e6.
    View in: PubMed
    Score: 0.004
  50. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology. 2014 Mar; 59(3):1073-83.
    View in: PubMed
    Score: 0.004
  51. Genetics of drug-induced hepatotoxicity toxicity in Gilbert's syndrome. Am J Gastroenterol. 2013 Dec; 108(12):1936-7.
    View in: PubMed
    Score: 0.004
  52. Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer. 2013 Nov 09; 13:534.
    View in: PubMed
    Score: 0.004
  53. Haemophagocytic lymphohistiocytosis presenting as liver failure following Epstein-Barr and prior hepatitis A infections. BMJ Case Rep. 2013 Aug 13; 2013.
    View in: PubMed
    Score: 0.004
  54. PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-na?ve HCV genotype 1/4 patients. Hepatology. 2013 Aug; 58(2):524-37.
    View in: PubMed
    Score: 0.004
  55. JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-na?ve HCV genotype 1/4 patients. Hepatology. 2013 Aug; 58(2):514-23.
    View in: PubMed
    Score: 0.004
  56. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013 Jun 15; 381(9883):2100-7.
    View in: PubMed
    Score: 0.004
  57. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol. 2013 Mar; 58(3):479-87.
    View in: PubMed
    Score: 0.004
  58. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol. 2013 Jan; 11(1):81-87.e4; quiz e5.
    View in: PubMed
    Score: 0.004
  59. Low rates of hepatitis B virus screening at the onset of chemotherapy. J Oncol Pract. 2012 Jul; 8(4):e32-9.
    View in: PubMed
    Score: 0.004
  60. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31; 364(13):1207-17.
    View in: PubMed
    Score: 0.003
  61. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010 Sep; 52(3):822-32.
    View in: PubMed
    Score: 0.003
  62. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010 Aug 28; 376(9742):705-16.
    View in: PubMed
    Score: 0.003
  63. Interaction of CD44 and hyaluronic acid enhances biliary epithelial proliferation in cholestatic livers. Am J Physiol Gastrointest Liver Physiol. 2008 Aug; 295(2):G305-12.
    View in: PubMed
    Score: 0.003
  64. Chyloperitoneum with collateral lymphatic drainage involving abdominal skin. Dig Dis Sci. 1987 Jun; 32(6):660-4.
    View in: PubMed
    Score: 0.003
  65. Transmission of hepatitis B virus by artificial insemination. JAMA. 1987 Feb 27; 257(8):1079-81.
    View in: PubMed
    Score: 0.003
  66. Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series. Am J Transplant. 2006 Sep; 6(9):2177-82.
    View in: PubMed
    Score: 0.002
  67. Management of patients with cirrhosis in Southern California: results of a practitioner survey. J Clin Gastroenterol. 2006 Feb; 40(2):156-61.
    View in: PubMed
    Score: 0.002
  68. Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors. J Gastroenterol Hepatol. 2006 Feb; 21(2):381-3.
    View in: PubMed
    Score: 0.002
  69. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005 Nov; 42(5):1194-202.
    View in: PubMed
    Score: 0.002
  70. Morbidity in live liver donors: standards-based adverse event reporting further refined. Arch Surg. 2005 Sep; 140(9):888-95; discussion 895-6.
    View in: PubMed
    Score: 0.002
  71. Ultrastructural immunocytochemical localization of the asialoglycoprotein receptor in rat hepatocytes. Gastroenterology. 1984 Oct; 87(4):763-9.
    View in: PubMed
    Score: 0.002
  72. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol. 2004 Sep; 28(9):1204-11.
    View in: PubMed
    Score: 0.002
  73. Limited role for CXC chemokines in the pathogenesis of alpha-naphthylisothiocyanate-induced liver injury. Am J Physiol Gastrointest Liver Physiol. 2004 Sep; 287(3):G734-41.
    View in: PubMed
    Score: 0.002
  74. Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent. Aliment Pharmacol Ther. 2004 May 01; 19(9):1033-9.
    View in: PubMed
    Score: 0.002
  75. Cellular distribution of the asialoglycoprotein receptor in rat liver. Implications for hepatic accumulation of desialylated lymphocytes. Gastroenterology. 1984 Jan; 86(1):142-9.
    View in: PubMed
    Score: 0.002
  76. Epidemiology and clinical course of liver diseases: identification of candidates for hepatic transplantation. Hepatology. 1984 Jan-Feb; 4(1 Suppl):84S-94S.
    View in: PubMed
    Score: 0.002
  77. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology. 2003 Aug; 125(2):298-303.
    View in: PubMed
    Score: 0.002
  78. Relationship of pretransplant hepatobiliary disease to bile duct damage occurring in the liver allograft. Hepatology. 1983 Jan-Feb; 3(1):84-9.
    View in: PubMed
    Score: 0.002
  79. Hepatic injury by prescription medication. Med Sect Proc. 1983; 79-86.
    View in: PubMed
    Score: 0.002
  80. Hepatitis C therapy with long term remission after renal transplantation. Int J Artif Organs. 2002 Dec; 25(12):1189-93.
    View in: PubMed
    Score: 0.002
  81. Retrospective analysis of the results of liver transplantation for adults with severe hepatopulmonary syndrome. Liver Transpl. 2002 Oct; 8(10):925-31.
    View in: PubMed
    Score: 0.002
  82. Inflammatory pseudotumor of the liver as the first manifestation of Crohn's disease. Am J Gastroenterol. 2001 Aug; 96(8):2520-2.
    View in: PubMed
    Score: 0.002
  83. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol. 1999 Jan; 94(1):241-8.
    View in: PubMed
    Score: 0.001
  84. Mycotic aneurysm of arterial conduit presenting as massive upper gastrointestinal hemorrhage after liver transplantation. Liver Transpl Surg. 1998 Sep; 4(5):435-6.
    View in: PubMed
    Score: 0.001
  85. Survey results of transplant patients' attitudes on xenografting. Psychosomatics. 1998 Jul-Aug; 39(4):379-83.
    View in: PubMed
    Score: 0.001
  86. Incorporation of radiocopper into ceruloplasmin in normal subjects and in patients with primary biliary cirrhosis and Wilson's disease. Gastroenterology. 1978 Apr; 74(4):652-60.
    View in: PubMed
    Score: 0.001
  87. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology. 1998 Jan; 27(1):213-22.
    View in: PubMed
    Score: 0.001
  88. In vitro cell-mediated cytotoxicity in primary biliary cirrhosis and chronic hepatitis. Dysfunction of spontaneous cell-mediated cytotoxicity in primary biliary cirrhosis. J Clin Invest. 1977 Nov; 60(5):1116-28.
    View in: PubMed
    Score: 0.001
  89. Hepatitis C virus is not recoverable from liver tissue in cryptogenic cirrhosis: failure to identify hepatitis C virus-RNA using reverse transcription-mediated polymerase chain reaction. Hum Pathol. 1996 Nov; 27(11):1161-5.
    View in: PubMed
    Score: 0.001
  90. Transjugular intrahepatic portosystemic shunt: efficacy for the treatment of portal hypertension and impact on liver transplantation. Am Surg. 1996 Oct; 62(10):835-9.
    View in: PubMed
    Score: 0.001
  91. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation. Transplant Proc. 1996 Apr; 28(2):1011-3.
    View in: PubMed
    Score: 0.001
  92. Clearance of chronic hepatitis B virus infection in young children after alpha interferon treatment. J Pediatr. 1995 Nov; 127(5):815-8.
    View in: PubMed
    Score: 0.001
  93. Portal vein patency in candidates for liver transplantation: MR angiographic analysis. Radiology. 1995 Oct; 197(1):147-52.
    View in: PubMed
    Score: 0.001
  94. Effect of splenectomy of hepatic bilirubin clearance in patients with hereditary spherocytosis. Implications for the diagnosis of Gilbert's syndrome. J Lab Clin Med. 1981 Jul; 98(1):37-45.
    View in: PubMed
    Score: 0.000
  95. Receptor specific clearance by the reticuloendothelial system in chronic liver diseases. Demonstration of defective C3b-specific clearance in primary biliary cirrhosis. J Clin Invest. 1978 Nov; 62(5):1069-77.
    View in: PubMed
    Score: 0.000
  96. Abnormal hepatic transport of indocyanine green in Gilbert's syndrome. Gastroenterology. 1976 Mar; 70(3):385-91.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.